BioAdvance, the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania
, announced on April 16, 2009, that Philip P. Gerbino, PharmD., has been elected as Chair of the organization’s Board of Directors effective April 2009. BioAdvance also announced that John M. Daly, M.D., has joined the organization’s Board of Directors.
“We are honored to have Dr. Gerbino serve as Chair of the Board of Directors as he is nationally recognized for his professional accomplishments, and he is a tremendous advocate for the Greater Philadelphia region’s scientific strengths. He will be a strong voice for BioAdvance’s activities and a driving force for our organization’s future goals,” said Barbara S. Schilberg, managing director and CEO of BioAdvance.
As President of University of the Sciences in Philadelphia
for the past 14 years, Dr. Gerbino has helped guide the growth of the 188-year-old institution from its roots as Philadelphia College of Pharmacy and Science (PCPS) into the five colleges that now comprise the University. Dr. Gerbino is a Fellow of the College
, the American Pharmacists Association (APhA), Academy of Pharmacy Practice
and Management, and the American Society of Consultant Pharmacists (ASCP). He was the 2006 recipient of the Phi Lambda Sigma-Procter & Gamble National Leadership Award.
“I look forward to the opportunities ahead as BioAdvance expands on its successes of investing in and growing our region’s next-generation of leading biosciences companies, as well as in advancing the region’s prominence as a hub for life science discovery and entrepreneurship,” said Dr. Gerbino, who has served on BioAdvance’s Board of Director’s for the past six years. “BioAdvance has successfully helped its portfolio companies attract nearly $1 billion in additional capital to the region, built bridges between academic institutions and businesses through initiatives such as the Greater Philadelphia Bioinformatics Alliance and the Greater Philadelphia Life Sciences Guide, and led two Milken Institute studies on the impact of biosciences on our region. This dedication and leadership fulfills our covenant which fosters commercialization and regional economic development.”
Dr. Gerbino continues to serve on editorial and advisory boards of pharmacy, medical, and healthcare publications, and is a consultant on strategic planning, marketing, and new business development to the pharmaceutical and healthcare industries. He has or continues to serve on boards of private and public healthcare companies, and regional professional and civic organizations, including the University City Science Center
, the University City Keystone Innovation Zone, Quaker BioVentures, and Pennsylvania Bio.
An accomplished professional chairman and facilitator, Dr. Gerbino has published and lectured extensively. He served as President of APhA in 1990, and as a civilian pharmacy consultant to the Air Force Surgeon General. Prior to being named President at University of the Sciences, he served as Dean of the School of Pharmacy and Vice President of Academic Affairs. He also retains the title of “Linwood F. Tice Professor” at the Philadelphia College of Pharmacy. Dr. Gerbino earned his B.S. in Pharmacy and his PharmD. from PCPS where he has worked for more than 30 years as an educator and administrator.
John M. Daly, MD, FACS, FRCPS (Hon. Glasg.), has also joined BioAdvance as a board member. “Dr. Daly is a terrific addition to the BioAdvance Board of Directors,” said Ms. Schilberg. “Since he joined Temple University School of Medicine as Dean in 2002, the institution has increased its funding from NIH and has expanded its research focus in important disease areas such as obesity, virology and oncology, as well as clinical translational research. We look forward to increased opportunities to work with Temple
in advancing innovative new biomedical products.”
Since its first investments in 2003, BioAdvance has committed $15.5 million to 25 life sciences companies and 15 pre-seed projects. BioAdvance investments have enabled its portfolio companies to leverage almost $1 billion in subsequent capital into the region from private equity, grants, collaborations and M&A activity. Six companies have been acquired, including Acuity Pharmaceuticals, Alteris Therapeutics, and Protez Pharmaceuticals. BioAdvance portfolio companies are working to develop products to treat health problems including Alzheimer’s disease, cancer, diabetes, head trauma and infectious diseases. For more information visit www.bioadvance.com